TaiwanJ Pharmaceuticals Co (ROCO:6549) EBIT: NT$-24.29 Mil (TTM As of Dec. 2025)


ROCO:6549 TaiwanJ Pharmaceuticals Co Ltd ROCO:6549
42 GF Score
Price NT$7.13
GF Value NT$11.94
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is TaiwanJ Pharmaceuticals Co EBIT?

TaiwanJ Pharmaceuticals Co ROCO:6549 -0.83% 42 EBIT is NT$-24.29 Mil as of Dec. 2025. GuruFocus rates ROCO:6549 with a GF Score™ of 42/100 and a GF Value™ of NT$11.94 (Possible Value Trap). The stock has 2 warning signs investors should review.

TaiwanJ Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-11.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-24.29 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TaiwanJ Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 was -328.96%. TaiwanJ Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -553.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TaiwanJ Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -4.81%.


TaiwanJ Pharmaceuticals Co  (ROCO:6549) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TaiwanJ Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-27.108 * ( 1 - 0% )/( (11.408 + 5.073)/ 2 )
=-27.108/8.2405
=-328.96 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

TaiwanJ Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.214/( ( (3.055 + max(2.086, 0)) + (2.252 + max(0.99200000000001, 0)) )/ 2 )
=-23.214/( ( 5.141 + 3.244 )/ 2 )
=-23.214/4.1925
=-553.70 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.513) - (3.326 + 0 + 0.101)
=2.086

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.529) - (4.351 + 0 + 0.186)
=0.99200000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TaiwanJ Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-24.291/505.234
=-4.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiwanJ Pharmaceuticals Co EBIT Related Terms


TaiwanJ Pharmaceuticals Co EBIT Historical Data

* Premium members only.

The historical data trend for TaiwanJ Pharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiwanJ Pharmaceuticals Co EBIT Chart

TaiwanJ Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.30 -92.46 -3.75 -22.33 -24.29

TaiwanJ Pharmaceuticals Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.06 -9.68 -12.65 -12.68 -11.61

ROCO:6549 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, TaiwanJ Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiwanJ Pharmaceuticals Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiwanJ Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TaiwanJ Pharmaceuticals Co's EV-to-EBIT falls into.


ROCO:6549
42GF Score
TaiwanJ Pharmaceuticals Co Ltd ROCO:6549
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiwanJ Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-24.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-24.29 Mil mean?
TaiwanJ Pharmaceuticals Co (ROCO:6549) has a EBIT of NT$-24.29 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TaiwanJ Pharmaceuticals Co.
Is TaiwanJ Pharmaceuticals Co's EBIT too high?
TaiwanJ Pharmaceuticals Co's current EBIT is NT$-24.29 Mil. Overall, TaiwanJ Pharmaceuticals Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TaiwanJ Pharmaceuticals Co's EBIT compare to VRTX and REGN?
TaiwanJ Pharmaceuticals Co's EBIT of NT$-24.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TaiwanJ Pharmaceuticals Co. TaiwanJ Pharmaceuticals Co's current EBIT is NT$-24.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiwanJ Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, TaiwanJ Pharmaceuticals Co (ROCO:6549) is currently considered Possible Value Trap. The stock's GF Value™ is NT$11.94, compared to a current price of NT$7.13 — trading 40.3% below its estimated fair value. The current EBIT is NT$-24.29 Mil. TaiwanJ Pharmaceuticals Co's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TaiwanJ Pharmaceuticals Co (ROCO:6549), the current EBIT is NT$-24.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiwanJ Pharmaceuticals Co (ROCO:6549) Overvalued in 2026?

Based on GuruFocus' analysis, TaiwanJ Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$7.13 is trading 40.3% below its estimated GF Value™ of NT$11.94. GuruFocus considers TaiwanJ Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6549:

  • EBIT: NT$-24.29 Mil
  • GF Value™: NT$11.94 vs. price of NT$7.13 (40.3% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiwanJ Pharmaceuticals Co Business Description

Address No. 6-1, Shengyi Road, 3F-4, Section 2, Hsinchu County, Zhubei, TWN, 30261
TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.
42GF Score

Get the complete analysis for ROCO:6549

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$7.13
Price
NT$11.94
GF Value